Related Experiment Video

Updated: May 22, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
03:49

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Medicare program; changes to the Medicare Advantage and the Medicare prescription drug benefit programs for contract

    Federal Register
    |May 22, 2012
    PubMed

    Insights

    This final rule updates Medicare Advantage (Part C) and prescription drug benefit (Part D) regulations. Key changes include enhanced beneficiary protections and improved program efficiencies.

    Area of Science:

    • Healthcare policy
    • Medicare regulations
    • Pharmaceutical benefits

    Background:

    • Existing Medicare Advantage (Part C) and Part D regulations require updates to align with new legislation.
    • There is a need to strengthen protections for beneficiaries enrolled in Medicare health and drug plans.
    • Program efficiencies and clarity in requirements are essential for effective administration.

    Purpose of the Study:

    • To revise Medicare Advantage (Part C) and prescription drug benefit (Part D) regulations.
    • To implement new statutory requirements and strengthen beneficiary protections.
    • To improve program efficiencies, exclude underperforming plans, and clarify requirements, including those for long-term care pharmacy services.

    Main Methods:

    • Publication of a final rule with comment period.
    • Revision of existing Medicare Advantage (Part C) and Part D regulations.
    • Incorporation of public comments on pharmacy services in long-term care facilities.

    Main Results:

    • Updated regulations for Medicare Advantage (Part C) and Part D programs.
    • Implementation of new statutory mandates.
    • Strengthened safeguards for Medicare beneficiaries.
    • Provisions for excluding poorly performing plan participants.
    • Enhanced program efficiencies and clarified operational requirements.
    • Response to public comments on long-term care facility pharmacy conditions.

    Conclusions:

    • The revised regulations aim to enhance the integrity and effectiveness of the Medicare Advantage and Part D programs.
    • Beneficiary protections and program oversight are significantly strengthened.
    • The rule clarifies requirements and addresses specific concerns, such as pharmacy services in long-term care settings.

    More Related Videos

    A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings06:59

    A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

    Published on: November 9, 2016

    Related Concept Videos

    FDA Approved Drugs: Changes to Approved Drugs01:26

    FDA Approved Drugs: Changes to Approved Drugs

    Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
    Prescription, Nonprescription and Orphan Drugs01:02

    Prescription, Nonprescription and Orphan Drugs

    Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
    The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
    Drug Products: Biologics, Biosimilars and Interchangeables01:28

    Drug Products: Biologics, Biosimilars and Interchangeables

    Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
    Standards of Care II01:19

    Standards of Care II

    Nurses bear specific legal responsibilities under several federal statutes, including: